A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of LY3839056 in Healthy Participants
A Phase 1, Randomized, Placebo-Controlled, Investigator- and Participant-Blinded, Single Ascending Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of LY3839056 in Healthy Participants
The main purpose of this study is to see if LY3839056 is safe and well tolerated when given as a single dose into a vein intravenous (IV) or under the skin subcutaneous (SC) in healthy participants. The study will also measure how much LY3839056 gets into the blood and how long it takes the body to remove it. The study will last up to 17 weeks and includes a stay of about 6 days at the clinical research unit.
調査の概要
研究の種類
入学 (推定)
段階
- フェーズ 1
連絡先と場所
研究連絡先
- 名前:1-877-CTLILLY (1-877-285-4559) or
- 電話番号:1-317-615-4559
- メール:LillyTrials@lilly.com
研究場所
-
-
Shanghai Municipality
-
Shanghai、Shanghai Municipality、中国、200040
- Huashan Hospital, Fudan University (复旦大学附属华山医院) 12 Urumqi Middle Road
-
コンタクト:
- Xiaojie Wu, PhD
- 電話番号:13524686330
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Key Inclusion Criteria:
- Are overtly healthy as determined by medical evaluation, including medical history, physical examination, laboratory tests, and Cardiac Monitoring.
- Have clinical laboratory test results within normal reference range for the population or the clinical research site, or results with acceptable deviations that are judged to be not clinically significant by the investigator.
- Have venous access sufficient to allow for IV drug delivery and blood sampling as per the protocol.
- Have a body mass index within the range of 18.0 to 32.0 kg/m².
- Participants assigned male or female at birth, including individuals of childbearing potential (IOCBP), may participate in this trial.
- Contraceptive use by participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
Key Exclusion Criteria:
- Are immunocompromised or have a history of a primary immunodeficiency, splenectomy, or any underlying condition that predisposes the participant to infection.
- Have a history or presence of cardiovascular, respiratory, hepatic, ophthalmological, renal, gastrointestinal, endocrine, hematological, neurological, or psychiatric disorders.
- Had any surgical procedure (except for minor surgery requiring local or no anesthesia and without any complications or sequelae) within 12 weeks prior to screening, or any planned surgical procedure scheduled to occur during the study.
- Have a clinically significant history of multiple or severe allergies or an anaphylactic reaction to prescription or nonprescription drugs or food.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:基礎科学
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:ダブル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Cohort 1 IV
Participants will receive LY3839056 Intravenously |
LY3839056 Administered Intravenously
他の名前:
|
|
実験的:Cohort 2 IV
Participants will receive LY3839056 Intravenously |
LY3839056 Administered Intravenously
他の名前:
|
|
実験的:Cohort 3 IV
Participants will receive LY3839056 Intravenously |
LY3839056 Administered Intravenously
他の名前:
|
|
実験的:Cohort 4a IV
Participants will receive LY3839056 Intravenously |
LY3839056 Administered Intravenously
他の名前:
|
|
実験的:Cohort 4b SC
Participants will receive LY3839056 Subcutaneously |
LY3839056 Administered Subcutaneously
他の名前:
|
|
実験的:Cohort 5 IV
Participants will receive LY3839056 Intravenously |
LY3839056 Administered Intravenously
他の名前:
|
|
実験的:Cohort 6a IV
Participants will receive LY3839056 Intravenously |
LY3839056 Administered Intravenously
他の名前:
|
|
実験的:Cohort 6b SC
Participants will receive LY3839056 Subcutaneously |
LY3839056 Administered Subcutaneously
他の名前:
|
|
プラセボコンパレーター:Placebo IV
Participants will receive Placebo Intravenously |
Placebo Administered Intravenously
他の名前:
|
|
プラセボコンパレーター:Placebo SC
Participants will receive Placebo Subcutaneously |
Placebo Administered Subcutaneously
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
To evaluate the safety and tolerability of LY3839056 following single-dose administration (IV or SC) in healthy participants.
時間枠:Baseline through Day 85
|
Frequency of AEs, TEAEs, SAEs, and Discontinuation due to TEAEs. |
Baseline through Day 85
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
PK: Cmax
時間枠:Predose on Day 1 up to Day 85
|
Maximum Observed Concentration (Cmax) of LY3839056 following single SC or IV dose |
Predose on Day 1 up to Day 85
|
|
PK: AUC
時間枠:Predose on Day 1 up to Day 85
|
Area Under the Concentration Versus Time Curve (AUC) of LY3839056 following single SC or IV dose |
Predose on Day 1 up to Day 85
|
|
PK: t1/2
時間枠:Predose on Day 1 up to Day 85
|
Half Life (t1/2) of LY3839056 following single SC or IV dose |
Predose on Day 1 up to Day 85
|
|
PK: F%
時間枠:Predose on Day 1 up to Day 85
|
Bioavailability (F%) of LY3839056 following single SC dose |
Predose on Day 1 up to Day 85
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)、Eli Lilly and Company
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- 27924
- J7H-MC-KAAB (その他の識別子:Eli Lilly and Company)
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。